I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

July 31, 2003

Glenn P. Ladwig, Patent Attorney

SEQUENCE LISTING SUBMISSION

UNDER 37 C.F.R. § 1.821

Examining Group 1632

Patent Application

Docket No. UF-221C1XC1

Serial No. 09/662,254

TECH CENTER 1600/2900 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Anne Marie Sabrina Wehbe

Art Unit

1632

Applicants

Richard W. Moyer, Yi Li, Alison Louise Bawden

Serial No.

09/662,254

Filed

September 14, 2000

Confirm. No. :

2442

For

Materials and Methods for Delivery and Expression of Heterologous DNA

in Vertebrate Cells

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE LISTING AND STATEMENT UNDER 37 C.F.R. §§ 1.821-1.825

In compliance with 37 C.F.R. §§ 1.821 through 1.825, transmitted herewith is a sequence listing in computer readable form and on paper.

I hereby certify that the attached sequence listing in computer readable form is identical to the attached paper copy of the sequence listing and that no new material is introduced by this submission.

Respectfully submitted,

Glenn P. Ladwig Patent Attorney

Registration No. 46,853

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

Saliwanchik, Lloyd & Saliwanchik

2421 N.W. 41st Street, Suite A-1 Gainesville, FL 32606-6669

GPL/mv

Attachments: Sequence Listing on Paper

Sequence Listing in Computer Readable Form (disk)

AUG 0 4 2003

Application No.: 09/662/254

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING! NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: The nucleotide or amino acid sequences in Figures 10 and 12 are not identified by SEQ ID NOS.
Applicant Must Provide:	
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	CRF Submission Help, call (703) 308-4212 PatentIn software help, call (703) 308-6856
. 0	1 GLOTHAL SOLWALE HEID. CALLI (1001 500-0050

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE